Since ancient times, larval therapy has been reputed to help wound healing. Its use has recently been rediscovered and it is now enjoying increasing interest in clinical practice, as well as in research. We have investigated the effects of larval therapy on wounds in an open study of 74 patients with necrotic or sloughy chronic ulcers of different aetiologies. We found larval therapy to effectively debride 86% of the necrotic ulcers, and a single application was clinically beneficial in two-thirds of the patients. Failure to debride was mostly attributable to larval death. No ulcer type was shown to be more suited to larval therapy than others; however, there was an excellent response in all 29 patients with diabetes. Larval therapy was also noted to reduce odour in 58% of the 31 foul-smelling ulcers of mixed aetiology. No serious side-effects were observed. One-quarter of the study group experienced less pain during treatment, while 41% felt no difference in pain, and, although 34% noted an increase in pain, most of these patients wanted to continue the treatment because of subjective and objective visual improvement in wound debridement. In conclusion, we found larval therapy to be effective for debriding ulcers, easy to use and well accepted by the patients.
Introduction
The increasing number of elderly people in most populations in the industrial world is leading to an increase in the number of chronic ulcers of multifactorial origin being presented for treatment. These ulcers often harbour necrosis or at least fibrin slough. The removal of necrotic tissue by debridement is thought to be one of the most important steps in wound management, although the scientific evidence for debriding chronic ulcers has been questioned. 1, 2 Several methods of debridement can be used: autolytic, mechanical, surgical (sharp) and biological. 2 Autolytic debridement in a moist environment is slow and sometimes insufficient, although it is the most selective method of all. 2 Mechanical and especially sharp surgical debridement requires skilled personnel and is, even so, unselective and painful, and includes the risk of blood shedding. Biological ulcer debridement using the larvae of flies is traditionally well known. 3, 4 Several types of larva from flies, including the larvae of the common housefly, Musca domestica, have been isolated from accidentally infested wounds. The larvae of the housefly are, however, not effective enough for clinical use. The larvae of other fly species can be very aggressive and invade healthy tissue, causing myiasis. 4 The blowfly, Lucilia sericata, is the most frequently used species for wound treatment as it is effective and feeds only on necrotic tissue. [5] [6] [7] [8] [9] Larval therapy was an established method in the USA for treating chronic ulcers and osteomyelitis in the 1930s. 4, [10] [11] [12] [13] There has been growing interest in the revival of this method since Sherman et al. conducted a study of larval therapy with favourable results in the 1990s. 5 The aim of this study was to investigate whether the larvae of the blowfly, L. sericata, can effectively debride chronic ulcers.
Patients, methods and larvae
Seventy-four patients with chronic (duration at least 6 weeks) necrotic or sloughy ulcers were included in an open study that was continued for 3 years. The median age of the patients (43 female and 31 male) was 72 years (range 25-94 years), and 39% (29 ⁄ 74) had diabetes. Each patient and often a close relative were informed of the method both orally and in writing. All the patients gave their informed consent. The local ethics committee approved the study.
The study was performed in collaboration with other dermatological departments in the County of Västra Götaland. Most patients (55) were treated at Sahlgrenska University Hospital in Göteborg. Before and after each treatment, a report was completed and a photograph taken. The report included information about the type of ulcer (see Table 1 ), the amount of necrosis, slough and odour, registration of pain using a visual analogue scale (VAS), and side-effects such as tickling ⁄ itching, bleeding and psychologically adverse reactions.
Photographs and reports were reviewed at the end of the study by one of the authors (H.W.).
The larvae of Lucilia sericata were initially imported from the Surgical Materials Testing Laboratory, Bridgend, UK.
14 In 1998, we started our own fly laboratory in order to have a steady supply of larvae. The larvae were microbiologically tested before use to certify that no infection would be induced by the larval therapy.
One-day-old larvae were inserted in the wound, at about 5 to 10 larvae ⁄ cm 2 .
To prevent larvae escaping from the wound, a Tegapore net (3M, St. Paul, MN) was placed over the wound and secured to a ring of hydrocolloid dressing (Duoderm, Convatec, Deeside, UK) with an adhesive Sleek tape (Smith and Nephew, Hull, UK). The larvae were removed when fully grown (1 cm long) after 1 to 3 days (Fig. 1) .
Results
Ninety-three per cent (69 ⁄ 74) of the ulcers contained necrotic tissue and 7% (5 ⁄ 74) fibrin slough. In 86% (59 ⁄ 69) of the patients with necrotic ulcers, the ulcer area was debrided to between 66 and 100% (Fig. 2) . The remaining necrotic ulcers were considered failures, as were the five sloughy ulcers. Most failures were caused by larval death.
One larval application was performed in 72% (53 ⁄ 74), two consecutive treatments in 19% (14 ⁄ 74) and three or four treatments in 9% (7 ⁄ 74) of patients. Thirty-nine per cent (29 ⁄ 74) of the patients had diabetes, and in these patients all ulcers, regardless of origin, had necrotic tissue and were well debrided.
Malodour was experienced in 42% (31 ⁄ 74) of the ulcers, and was reduced in 58% (18 ⁄ 31) of these cases by larval therapy. One wound was more malodorous after treatment than before, even though it was well debrided.
Most patients (82%; 61 ⁄ 74) were able to describe in 'VAS units' their pain experience during larval treatment. Thirty-four per cent (21 ⁄ 61) felt increased pain during treatment, which led to interrupted therapy in four cases. Less pain than before treatment was felt in 
Discussion
In our clinical experience, debridement is an important step in wound treatment, and larval therapy has in many patients resulted in remarkably rapid ulcer debridement and generation of granulation tissue. Accelerated wound healing has also been observed. However, many people, especially professionals, are still sceptical about larval therapy. More scientific proof of its efficacy has been called for, and more clinical studies on the effects of larval therapy have been felt to be required. It is also necessary to determine more precisely the types of ulcers in which larval therapy is most beneficial. A clinical study on larval therapy presents special problems and cannot, for example, be performed as a double-blind study. The patients had all been using autolytic debridement methods before entering the study without satisfactory results. In this open study, we established that larval therapy resulted in good debridement and also had an effect on malodour. The inclusion criteria in this study were necrotic or sloughy chronic wounds. As we included all types of ulcers and even critically ill patients, we were unable to evaluate outcomes in terms of healing or decreases in wound size. In this study, there was no noticeable association between debridement and wound origin. We observed, however, that the larvae seemed to thrive especially well in the wounds of diabetic patients, which were all completely debrided.
Larval therapy is unique as a wound treatment and cannot really be compared with any other treatment. Use of larvae in wound treatment requires special attention to the creation of optimal conditions for the larvae, otherwise they will be crushed, dry out, suffocate or drown in the wound fluid. Compression therapy can kill the larvae by crushing them, which also can happen in foot ulcers while the patient is walking. Bed rest prevents the larvae being crushed and decreases leg oedema, which might increase wound exudation, increasing the risk of drowning the larvae. Bed rest during larval therapy is therefore often recommended and was used in this study. We have tried several other methods to prevent the larvae being crushed. One effective method is to create a deeper wound by using two layers of hydrocolloid dressing around the ulcer margins.
Drying out was the most common cause of larval therapy 'failure'. To prevent the larvae from drying out, a top dressing of gauze moistened with saline was applied to the net on the first day of treatment. Larvae can also dry out when a dry black necrosis covers the entire ulcer surface as the larvae cannot get underneath the eschar. The edges of the eschar were softened with a hydrogel a couple of days before applying the larvae in these cases. To avoid suffocation, the top dressing was lifted to allow air to penetrate down to the larvae twice daily.
One of the presumed risks of larval therapy is injury to blood vessels causing bleeding, which was not seen in this study. Larval treatment induces abundant granulation tissue in many cases, and insignificant superficial blood shedding from the new tissue is sometimes observed. We have not considered this bleeding to be a significant side-effect.
Other wound therapies or even systemic therapies may influence the larval effect. 15, 16 The patients in our study had been treated with many different types of wound-treatment products immediately before the initiation of larval therapy. This did not appear to be disadvantageous, as long as the wound was thoroughly cleansed of remnants of these products before starting larval therapy. No adverse effects on larval growth were observed in the wounds of patients to whom systemic antibiotics were administered at the same time. We observed that larval therapy was less efficient in the vasculitic ulcer and pyoderma gangrenosum ulcer. Because there was only one of each of these ulcers in this study, we can merely speculate on an association with the systemic medications of these patients.
In conclusion, in this study we found larval therapy not only to be effective in debriding necrotic ulcers, but also to be fast and very precise, as the larvae avoided healthy tissue. We were able to confirm the statement of Sherman et al. 5 that most necrotic ulcers were debrided within 1 week. It took two larval applications of 2 to 3 days each to debride a thick eschar, but a thin eschar could be debrided after only one larval application, regardless of ulcer origin.
